Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SBRT-IL2
Most Recent Events
- 17 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 21 Aug 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 24 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.